Canada should give biopharmaceutical firms patent term extensions to recover time lost due to mandatory regulatory and marketing approvals.
Canadian policy-makers should enact legislation to define rare diseases and encourage Canadian firms to intensify their research and development of new therapies, writes Kristina Lybecker. Victor Casale photograph courtesy of Flickr
VANCOUVER, B.C. / Troy Media/ – As the old adage states, “You’ll be known by the company you keep.” As such, the implications for Canada’s biopharmaceutical sector are rather dismal.
People. Policy. Politics. This is an exclusive subscriber-only story.
'You don't stop trying to find ways of resolving differences in opinion, but I do think in this day and age you need a whole range of ways of expressing concern and trying to move opinion,' says Bob Rae.
Government House Leader Pablo Rodriguez dodged questions if the government was responsible for setting the stage for a stand-off that could trigger an election, saying the question should be asked of the Conservatives.
Global Brief magazine editor Irvin Studin says politicians and policy-makers' thinking is 'too small, it’s too linear, it’s too path dependent, and it looks increasingly absurd as these systemic crises.'
Parliamentary Budget Officer Yves Giroux says he's found it 'much more difficult to get information out of the minister’s officer' since Parliament returned with Chrystia Freeland in charge of the nation's finances.